Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling


This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3 adenosine receptors.

Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions.

Potential Commercial Applications: Competitive Advantages:
  • Tools to study prevalence of this receptor on neutrophils, a predictor of response to agonist drugs.
 
  • Avoids the use of radioisotopes in this part of the R&D process.


Development Stage:
  • Early-stage
  • In vitro data available


Inventors:

Kenneth Jacobson (NIDDK)  ➽ more inventions...


Intellectual Property:
US Pat: 9,227,979 issued 2016-01-05
US Application No. 13/748,826 filed on 2013-01-24
(Note: a separate license may be required for the fluorescent portion of the molecule.)

Publications:
Kozma E, et al. PMID 22402302

Licensing Contact:
Betty Tong, Ph.D.
Email: tongb@niddk.nih.gov
Phone: 301-451-7836

OTT Reference No: E-073-2012-0
Updated: Feb 18, 2016